Aqueous flow is reduced by the alpha-adrenergic agonist, apraclonidine hydrochloride (ALO 2145).
Apraclonidine hydrochloride (ALO 2145), a clonidine derivative that does not cross the blood-brain barrier, was applied topically to one eye of each of 20 normal human subjects. The rate of aqueous humor flow and the permeability of the blood-aqueous barrier were measured by fluorophotometry. Four hours after administration, the flow rate in the apraclonidine-treated eyes was 35% lower than that measured in the control eyes. Three hours after instillation, the intraocular pressure (IOP) was 34% lower in the apraclonidine-treated eyes when compared with control eyes. Both these differences were statistically significant. The drug had little, if any, effect on blood-aqueous permeability.
Gharagozloo
N Z
NZ
Department of Ophthalmology, Mayo Clinic and Foundation, Rochester, Minnesota 55905.
Relf
S J
SJ
Brubaker
R F
RF
D000287:Administration, Topical; D000328:Adult; D001082:Aqueous Humor / Q000187:drug effects* / Q000378:metabolism; D003000:Clonidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D009883:Ophthalmic Solutions; D010539:Permeability; D010919:Placebos
D009883:Ophthalmic Solutions; D010919:Placebos; C016986:apraclonidine; D003000:Clonidine